Cephalon demands secret patent-settlement info

Cephalon asked a U.S. judge to order the Federal Trade Commission to release confidential documents on drug patent-litigation settlements throughout the pharma industry, saying it needs the documents defend against an FTC lawsuit that seeks to clear generic competition for the company's top-selling narcolepsy treatment Provigil. Report

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

Warren Buffett's Berkshire Hathaway has built a $192 million stake in Biogen, a risky investment considering aducanumab's uncertain future.